Amine Addition Salt Of The Acid Patents (Class 514/554)
  • Patent number: 11103545
    Abstract: The present invention relates to a composition a maximum of six, in particular a maximum of five or four different plant extracts for use in the prevention and/or treatment of diabetes type II or type 1. At least one plant extract has antioxidative properties and/or antioxidant enzyme inducing properties; at least one plant extract has anti-inflammatory properties; at least one plant extract has immune modulating properties; and at least one plant extract has neuronal hormone modulating properties.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: August 31, 2021
    Inventor: Shanta Banerjee
  • Patent number: 11077138
    Abstract: The disclosure provides local delivery of a trace element to a site of tissue injury, which triggers the body' inherent tissue repair mechanism. Local delivery of copper to the site of injury induces migration (i.e., homing) of stem cells to the site of injury, triggers differentiation of stem cells at the site of injury, induces tissue regeneration at the site of injury, induces signaling molecules that trigger tissue regeneration, reverses damage at the site of injury, and/or reconstructs the microenvironment of neurofibril cells and neurosecretory cells at the site of injury. In another aspect, delivering a trace element (for example, copper) directly to the site of injury and associated methods are disclosed.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: August 3, 2021
    Assignee: INNOLIFE CO., LTD.
    Inventor: Yujian James Kang
  • Patent number: 11021443
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 1, 2021
    Assignees: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Bruce P. Bean, Clifford J. Woolf, Jinbo Lee, Sooyeon Jo, David Roberson, Sebastien Talbot
  • Patent number: 10993951
    Abstract: The field of the present invention is that of fosfomycin formulations for parenteral administration, in particular for intravenous administration. Formulations of the prior art provide fosfomycin as a powder to be diluted directly prior to the administration. The aim of the invention is to provide a fosfomycin formulation for parenteral administration which is easier to produce and administer or which lowers the risk of puncture injuries for healthcare professionals and the health risks for the patients (for example due to contamination or incorrect dosages) by preventing additional processing steps. During the course of the invention, it was surprisingly shown that fosfomycin is much more stable in an aqueous solution than what is commonly assumed.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 4, 2021
    Inventors: Apostolos Georgopoulos, Albert Schifer, Wolfgang Rous
  • Patent number: 10709677
    Abstract: The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 14, 2020
    Assignee: INFLECTIS BIOSCIENCE
    Inventor: Philippe Guedat
  • Patent number: 10590070
    Abstract: Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 17, 2020
    Assignee: Alzheon, Inc.
    Inventors: Petr Kocis, Martin Tolar, John Hey
  • Patent number: 10342813
    Abstract: A terminally sterilized aqueous calcium gluconate solution comprising 1 to 15 wt. % calcium gluconate and from 1 to 19 wt. parts of calcium saccharate per 100 wt. parts of calcium gluconate packaged in a flexible plastic container with the remainder water.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 9, 2019
    Assignee: HQ SPECIALTY PHARMA CORPORATION
    Inventor: Joseph Pizza
  • Patent number: 10112851
    Abstract: The invention provides processes for purification of aqueous industrial liquids from perchlorate ions by reducing perchlorate ion concentration or by precipitating a water-insoluble perchlorate salts.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: October 30, 2018
    Assignee: Toxsorb Ltd.
    Inventor: Yotam Gonen
  • Patent number: 9770466
    Abstract: Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 26, 2017
    Assignee: Veloce BioPharma, LLC
    Inventors: Joseph Capriotti, Kara Capriotti, Jesse Pelletier, Kevin Stewart
  • Patent number: 9740119
    Abstract: The invention is to provide a positively charging electrostatic image developing toner capable of providing a high quality and high gloss and excellent in stability in long term use and environmental stability, and especially not causing fog in the use at high temperature and high humidity condition. The present invention relates to an electrostatic image developing toner comprising toner mother particles containing a binder resin and a colorant, wherein the binder resin contains a repeating unit having 4 to 20 ether bonds, containing a carbon atom, a hydrogen atom and an oxygen atom, and accounting for a specific amount.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 22, 2017
    Assignee: MITSUBISHI CHEMICAL CORPORATION
    Inventors: Usei Jo, Tetsuharu Yuge, Maki Saito, Masami Tsurumori
  • Patent number: 9675566
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 13, 2017
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Patent number: 9662287
    Abstract: A process for preparing acylglycinates of the formula (I) wherein R1 is a linear or branched, saturated alkanoyl group having 6 to 30 carbon atoms, or is a linear or branched, singly or multiply unsaturated alkenoyl group having 6 to 30 carbon atoms, and Q+ is a cation, wherein glycine is reacted with fatty acid chloride R1Cl, in water and in the presence of a basic alkali metal compound which yields cations Q+, but in the absence of organic solvents, at 25-50° C. Also described are compositions comprising acylglycinates of the formula (I).
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: May 30, 2017
    Assignee: Clariant International Ltd.
    Inventors: Peter Klug, Franz-Xaver Scherl
  • Patent number: 9402802
    Abstract: The present invention relates to a composition for topical administration comprising an ascomycin and a carrier vehicle comprising means to retain water in the outer skin layer and means to hinder water evaporating from the skin.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: August 2, 2016
    Assignee: MEDA Pharma SARL
    Inventors: Katrin Kriwet, Dorothea Ledergerber, Jutta Riedl
  • Patent number: 9339469
    Abstract: The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: May 17, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Muhammad Safadi, Anton Frenkel, Michal Keisar, Danit Licht, Eliezer Bahar, Ramy Lidor-Hadas, Marina Zholkovsky, Rachel Cohen
  • Patent number: 9242008
    Abstract: The present invention relates to compound of Formula III comprising an amino acid component, a divalent metal component, and a counter-ion component, compositions containing same, and methods of use.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: January 26, 2016
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias
  • Patent number: 9187407
    Abstract: A process of producing N-acyl amino acid based surfactants of Formula I, wherein, R is selected from C6 to C22 alkyl group, R1 is selected from H, C1 to C4 alkyl, R2 is selected from all groups on ? carbon of natural amino acids, R3 is selected from COOX, CH2—SO3X, X is selected from Li+, Na+ or K+. The process comprising steps of: A) preparing fatty acid chlorides by halogenating fatty acids with either phosgene or thionyl chloride in the presence of catalytic amount of same or other N-acyl amino acid surfactant of Formula I or anhydrides of same surfactant; and B) reacting fatty acid chloride of step (A) with an amino acid in the presence of a base.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: November 17, 2015
    Assignee: GALAXY SURFACTANTS LTD.
    Inventors: Nirmal Koshti, Bharat Bhikaji Parab, Rajendra Subhash Powale, Archana Kishor Desai, Kamlesh Keshwar Barai, Pradnya Mandar Katdare, Bhagyesh Jagannath Sawant, Santosh Vishnu Kadam, Srinivas Uppalaswamy Pilli
  • Patent number: 9012689
    Abstract: The present invention relates to a compound of formula A, wherein R is alkyl. Compound A may be used as an intermediate in the preparation of O-desmethyl venlafaxine or a salt thereof, and the present invention provides such a preparation, as well as a process for preparing the compound of formula A.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: April 21, 2015
    Assignee: Cipla Limited
    Inventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Manohar Raghunath Surve
  • Patent number: 8980919
    Abstract: The present invention relates to a medicament for treating occlusive and/or ischemic vascular disorder comprising a carbostyril derivative and carnitine.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: March 17, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Takao Urabe, Yuji Ueno, Kensuke Orito, Hiroshi Ohno
  • Patent number: 8952059
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 10, 2015
    Assignee: Sigma-Tau Industrie Faramceutiche Riunite S.p.A.
    Inventors: Antonino Amato, Menotti Calvani
  • Patent number: 8933124
    Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: January 13, 2015
    Inventors: Banavara L. Mylari, Frank C. Sciavolino
  • Patent number: 8933123
    Abstract: The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: January 13, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Rushikesh Udaykumar Roy
  • Patent number: 8916610
    Abstract: An acid addition salt of a nortriptyline-GABA conjugate, a novel crystalline form of a fumaric acid addition salt of a nortriptyline-GABA conjugate, and processes of preparing the forgoing are disclosed. Uses of the above-indicated forms of a nortriptyline-GABA conjugate in the treatment of CNS disorders, and in the treatment of pain in particular, are also disclosed. Further disclosed in a large-scale process of preparing a nortriptyline-GABA conjugate.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: December 23, 2014
    Assignees: Ramot at Tel-Aviv University Ltd., Bar-Ilan University
    Inventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman, Mazal Shaul, Efrat Halbfinger
  • Publication number: 20140364500
    Abstract: The present invention relates to compounds having the following structure: wherein R is H or OH and X+ is protonated metformin, protonated arginine, protonated lysine and protonated meglumine. The invention also relates to intermediates used in the preparation of such compounds, processes for the preparation of such compounds and intermediates, pharmaceutical compositions comprising such compounds and the methods of treatment using such compounds as antidiabetic, antiobesity, and antisarcopenia agents.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 11, 2014
    Inventors: Banavara L. Mylari, G. Alexander Fleming
  • Publication number: 20140323573
    Abstract: The present invention proposes novel salt compounds for use in the diagnosis or therapy of a patient as well as drugs, medical products, diagnostic compositions or blood products containing a salt compound according to the invention. The salt compounds according to the invention comprise the cation of a metabolisable basic amino acid and the anion of a metabolisable carboxylic acid or an anion of carbonic acid. Those salt compounds therefore have the advantage that they are fully metabolisable and thus do not adversely affect the electrolyte balance or the acid-base balance of the patient.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 30, 2014
    Inventor: Manfred Rüdinger
  • Publication number: 20140301998
    Abstract: Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by weight, based on the total weight of the formulation.
    Type: Application
    Filed: June 2, 2014
    Publication date: October 9, 2014
    Applicant: BEIERSDORF AG
    Inventors: Rainer KROPKE, Jens NIELSEN, Kathrin WOLTER
  • Publication number: 20140249221
    Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: Thetis Pharmaceuticals LLC
    Inventors: Banavara L. Mylari, Frank C. Sciavolino
  • Patent number: 8795993
    Abstract: A process is described for producing fermentable sugars derivable from biomass that contains polysaccharide, such as cellulose, made increasingly accessible as a substrate for enzymatic degradation or other methods of depolymerization. These fermentable sugars are subsequently able to be fermented to produce various target chemicals, such as alcohols, aldehydes, ketones or acids.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: August 5, 2014
    Assignee: Hercules Incorporated
    Inventors: Herbert T. Conner, Patrick J. Cowan, John C. Gast
  • Patent number: 8785496
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 22, 2014
    Assignee: Abbott Laboratories
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Patent number: 8779005
    Abstract: The invention deals with new salts of the desvenlafaxine base of formula (I) with oxalic acid, the new salts being the hydrogen oxalate of formula (II) in the proportion of desvenlafaxine:oxalic acid of 1:1 and hemioxalate of formula (III) in the proportion of desvenlafaxine:oxalic acid of 2:1.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: July 15, 2014
    Assignee: Zentiva k.s.
    Inventors: Ludek Ridvan, Petr Hruby, Stanislav Radl, Hana Brusova, Lukas Krejcik, Tomas Pekarek, Natalia Csokova, Anna Zerzanova
  • Publication number: 20140194510
    Abstract: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Keith Lorimer, David Engers
  • Patent number: 8734837
    Abstract: The development and growth of oviparous species such as birds is enhanced by in ovo administration of an enteric modulator such as HMB. The enteric modulator is administered into the amnion, where it is then orally ingested by the subject. The enteric modulator enhances the enteric development of the subject prior to hatch, and enhances the growth of the animal before and after hatch.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: May 27, 2014
    Assignees: North Carolina State University, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Zehava Uni, Peter R. Ferket
  • Publication number: 20140113965
    Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Type: Application
    Filed: December 27, 2013
    Publication date: April 24, 2014
    Applicant: DEY PHARMA, L.P.
    Inventors: Partha S. BANERJEE, Imtiaz A. CHAUDRY, Stephen PHAM
  • Patent number: 8691873
    Abstract: The invention provides a method of treating leukemia using a pharmaceutical composition containing bis-benzyl lipoate, triethanolamine, and a pharmaceutically acceptable diluent, where the bis-benzyl lipoate and triethanolamine form an ion pair.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: April 8, 2014
    Assignee: Cornerstone Pharmaceuticals, Inc.
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • Patent number: 8691872
    Abstract: The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 8, 2014
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Keith Lorimer, David Engers
  • Publication number: 20140079809
    Abstract: The use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for ophthalmic use, for the prevention or treatment of accomodative asthenopia is disclosed.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Nicola PESCOSOLIDO, Aleardo KOVERECH
  • Publication number: 20140057003
    Abstract: Device, system and method for electrochemical generation of a liquid soap by electrolyzing a surfactant in an aqueous carrier in a cathode compartment of an electrolytic cell and electrolyzing an antimicrobial agent in an aqueous carrier in an anode compartment of the electrolytic cell with the compartments separated by a semipermeable membrane. Portions of the electrolyzed surfactant solution and portions of the electrolyzed antimicrobial solution are withdrawn from the cathode compartment and the anode compartment and combined to form the liquid soap. Skin benefiting agents such as vitamins may be added to the liquid soap with the surfactant and/or antimicrobial agent.
    Type: Application
    Filed: August 23, 2013
    Publication date: February 27, 2014
    Inventor: Raymond C. Johnson
  • Publication number: 20140005616
    Abstract: Single layer and multi-layer anti-microbial wound care fabrics, gloves, sleeves, anklets, socks, finger cots, masks, and similar wound care articles are disclosed.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 2, 2014
    Applicant: Ansell Limited
    Inventors: JEFFREY MORELAND, ROGER EUGENE HUCKFELDT, DION ROSS, ERIC THOMPSON, JAMIE ASHWORTH, MICHAEL ZEDALIS, ANTHONY B. LOPEZ
  • Publication number: 20130295009
    Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof;
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventors: Torbjorn LUNDSTEDT, Anna SKOTTNER, Elisabeth SEIFERT
  • Publication number: 20130296427
    Abstract: Nerarnexane or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tinnitus, wherein said neramexane or a pharmaceutically acceptable salt thereof is administered to a patient afflicted with tinnitus caused by stress or acute hearing loss.
    Type: Application
    Filed: January 19, 2012
    Publication date: November 7, 2013
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Michael Althaus, Barbara Ellers-Lenz
  • Publication number: 20130289112
    Abstract: Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.
    Type: Application
    Filed: March 21, 2011
    Publication date: October 31, 2013
    Applicant: TIANJIN CHASESUN PHARMACEUTICAL CO., LTD
    Inventors: Jiang Zheng, Xinchuan Zheng, Xin Liu, Hong Zhou, Ning Wang, Hongwei Cao, Yan Li, Yongling Lu, Kecen Zhao, Jingcheng Yang, Yang Yang, Yuanfeng Zhu, Guo Wei, Min Huang
  • Patent number: 8569366
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: October 29, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Antonino Amato, Menotti Calvani
  • Patent number: 8568759
    Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 29, 2013
    Assignee: W. Neudorff GmbH KG
    Inventor: Diana L. Parker
  • Patent number: 8557863
    Abstract: Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors, e.g., by combining the two ingredients in an aqueous liquid such as grape juice and the ingredients are usefully provided in containers with instructions for use, especially with support of tests demonstrating the effectiveness of the treatment for, e.g., preventing tumors in populations known to be at risk of developing tumors, and, optionally, treating existing cancers with the combination and other cancer drugs such as anastrozole and/or fulvestrant.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 15, 2013
    Inventors: Robert Benson Aylor, Leigh Heather Makover, Robyn Aylor Haines
  • Patent number: 8536222
    Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: September 17, 2013
    Assignee: AlzChem AG
    Inventors: Thomas Gastner, Hans-Peter Krimmer
  • Patent number: 8518990
    Abstract: A method for treating, preventing or ameliorating a hyperliferative disease and/or disorder in a mammal, comprises administering a therapeutically effective amount of one or more compounds selected from the group consisting of a compound of Formula (III), a compound of Formula (IV), and a pharmaceutically acceptable salt of Formula (III) or Formula (IV): wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, vinyl and allyl.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: August 27, 2013
    Assignee: Oncophor, LLC
    Inventors: Gilles Klopman, Suman K. Chakravarti
  • Patent number: 8506989
    Abstract: The invention relates to a preparation comprising a creatine component, which has excellent bio-availability and leads to improved creatine retention in the human and animal body. The present invention further relates to a method for the production of said preparation, and to the use thereof as a nutritional supplement, functional food, animal feed additive, pharmaceutical, and as an additive for cosmetic and dermatologic formulations.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: August 13, 2013
    Assignee: AlzChem Trostberg GmbH
    Inventors: Thomas Gastner, Frauke Warrikoff, Barbara Nieβ, Josef Fuest
  • Publication number: 20130184347
    Abstract: An acid addition salt of a nortriptyline-GABA conjugate, a novel crystalline form of a fumaric acid addition salt of a nortriptyline-GABA conjugate, and processes of preparing the forgoing are disclosed. Uses of the above-indicated forms of a nortriptyline-GABA conjugate in the treatment of CNS disorders, and in the treatment of pain in particular, are also disclosed. Further disclosed in a large-scale process of preparing a nortriptyline-GABA conjugate.
    Type: Application
    Filed: September 22, 2011
    Publication date: July 18, 2013
    Applicants: Ramot at Tel-Aviv University Ltd., BioLineRX Ltd., Bar-llan University
    Inventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman, Mazal Shaul
  • Patent number: 8450330
    Abstract: A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: May 28, 2013
    Assignee: Yung Shin Pharmaceutical Industrial Co., Ltd.
    Inventors: Fangchen Lee, Hui-Ling Shieh, Chiung-Ju Tsai, Shin-Hong Jang
  • Publication number: 20130108564
    Abstract: The present invention relates to compounds having general formula (I): CH3—(CH?CH)n—R??(I) where: n=3, 5, 7; R is chosen from —CH2—O—CO—R?, —CO—OR? or —CO—O(?), R? is chosen from H, C1-C22 alkyl or alkenyl, aryl or aralkyl, or sugars; and their pharmaceutically acceptable salts, such as sodium, potassium and lysine salts, for use as the active ingredient in pharmaceutical or cosmetic compositions for improving the pigmentation of the human skin, treating pigmentation disorders and/or improve both the photoprotective capacity of the skin and the intensity of its suntan.
    Type: Application
    Filed: July 15, 2011
    Publication date: May 2, 2013
    Applicant: GIULIANI S.P.A.
    Inventors: Giammaria Giuliani, Ralf Paus, Yuval Ramot, Astrid Becker, Sergio Baroni
  • Patent number: RE44302
    Abstract: Compositions comprising N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl compounds are useful to alleviate or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors. N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl composition may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: June 18, 2013
    Inventors: Ruey J. Yu, Eugene J. Van Scott